Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;29(9):1391-1397.
doi: 10.1007/s10147-024-02557-5. Epub 2024 Jul 12.

The diagnostic and prognostic value of tartrate-resistant acid phosphatase isoform 5b for giant cell tumor of bone

Yu Toda  1   2 , Koichi Ogura  3 , Shintaro Iwata  1 , Eisuke Kobayashi  1 , Shuhei Osaki  1 , Suguru Fukushima  1 , Masaaki Mawatari  2 , Akira Kawai  1
Affiliations

The diagnostic and prognostic value of tartrate-resistant acid phosphatase isoform 5b for giant cell tumor of bone

Yu Toda et al. Int J Clin Oncol. 2024 Sep.

Abstract

Background: Serum level of tartrate-resistant acid phosphatase 5b (TRACP5b) is an excellent serum marker of bone resorption. In patients with giant cell tumor of bone (GCTB), TRACP5b levels are reportedly elevated. This study investigated whether TRACP5b could be a diagnostic serum marker and be useful for detecting postoperative disease progression for GCTB.

Methods: Cohort 1: We abstracted data from 120 patients with TRACP5b measurements from our database: 49 patients with GCTB and 71 patients non-GCTB. We compared serum TRACP5b values between the GCTB and non-GCTB groups. Cohort 2 included 47 patients with GCTB who had more than 6 months of follow-up and multiple TRACP5b values. For patients with local recurrence, TRACP5b change rate was calculated by comparing the TRACP5b value just before progression (a) with the value at the time of progression (b): Change rate = [(b)-(a)]/(a). In the non-progression group, the change rate was calculated from the two consecutive TRACP5b values, (c) and (d): Change rate =[(c)-(d)]/(c). We compared TRACP5b change rates between the progression and non-progression groups.

Results: Cohort 1: The GCTB group had a significantly higher mean TRACP5b value (1756 ± 2021 mU/dL) than the non-GCTB group (415 ± 219 mU/dL) (p < 0.0001). Cohort 2: The mean TRACP5b change rate of the progression group was significantly higher than the non-progression group (8.53 ± 8.52 and 0.24 ± 0.27, respectively; p < 0.0001).

Conclusion: TRACP5b is a useful diagnostic marker in GCTB. The rate of change in serum TRACP5b values is a highly sensitive marker for predicting local recurrence in GCTB.

Keywords: Bone tumor; GCTB (giant cell tumor of bone); Local recurrence; Tartrate-resistant acid phosphatase 5b (TRACP5b).

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. WHO Classification of Tumours, 5th ed, Vol 3, (2020) Soft tissue and Bone Tumours (ed by WHO Classification of Tumours Editorial Board), IARC, Lyon.
    1. Ogura K, Hosoda F, Nakamura H et al (2017) Highly recurrent H3F3A mutations with additional epigenetic regulator alterations in giant cell tumor of bone. Genes Chromosomes Cancer 56:711–718 - DOI - PubMed
    1. Yamamoto H, Iwasaki T, Yamada Y et al (2018) Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone. Hum Pathol 73:41–50 - DOI - PubMed
    1. Yamamoto H, Ishihara S, Toda Y et al (2020) Histone H3.3 mutation in giant cell tumor of bone: an update in pathology. Med Mol Morphol 53:1–6 - DOI - PubMed
    1. Amary F, Berisha F, Ye H et al (2017) H3F3A (Histone 3.3) G34W immunohistochemistry: a reliable marker defining benign and malignant giant cell tumor of bone. Am J Surg Pathol 41:1059–1068 - DOI - PubMed - PMC

LinkOut - more resources